Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZL-1201 · 1 trial · 1 indication
Incidence of Treatment-Emergent Adverse Events as Assessed by CTCAE v5.0
| Arm | Type | Description |
|---|---|---|
| Single arm, ZL-1201 | EXPERIMENTAL | Single arm, ZL-1201 |
| Name | Type | Description |
|---|---|---|
| ZL-1201 | DRUG | Part 1 \& 2: Escalating dose of ZL-1201, Part 3: three dose levels determined from Part 1 and Part 2. |
Inclusion Criteria: * Histologically/cytologically confirmed, locally advanced unresectable or metastatic solid tumors and lymphomas that are refractory or intolerant to standard of care therapy, or for which no standard therapy exists. * Adequate hematologic status * Adequate coagulation function ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ZL-1201 is an investigational small molecule being developed for the treatment of advanced cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with advanced cancer to evaluate its safety and potential efficacy.
ZL-1201 is being developed by Zai Lab Limited, a biopharmaceutical company traded on the NASDAQ under the ticker symbol ZLAB. The company is conducting clinical trials for this investigational oncology drug.
ZL-1201 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The Phase 1 trial has been completed, and the drug remains in early-stage clinical development for advanced cancer.
ZL-1201 has one completed clinical trial, identified as NCT04257617, titled "A Trial of ZL-1201 in Subjects With Advanced Cancer." This Phase 1 study enrolled 37 participants with advanced cancer and was conducted in the United States and China.
ZL-1201 is the primary name for this investigational drug. No alternative names have been reported for this compound. It is a small molecule being studied for its potential use in oncology.